Cerebrospinal Fluid Biomarkers in Clinical Subtypes of Early-Onset Alzheimer's Disease | Zendy

Edmond Teng | Zendy; Tritia R. Yamasaki | Zendy; Michelle Tran | Zendy; Julia J. Hsiao | Zendy; David L. Sultzer | Zendy; Mario F. Mendez | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cerebrospinal Fluid Biomarkers in Clinical Subtypes of Early-Onset Alzheimer's Disease

Author(s) -

Edmond Teng,

Tritia R. Yamasaki,

Michelle Tran,

Julia J. Hsiao,

David L. Sultzer,

Mario F. Mendez

Publication year - 2013

Publication title -

dementia and geriatric cognitive disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.026

H-Index - 110

eISSN - 1421-9824

pISSN - 1420-8008

DOI - 10.1159/000355555

Subject(s) - early onset alzheimer's disease , pittsburgh compound b , cerebrospinal fluid , posterior cortical atrophy , neurodegeneration , atrophy , medicine , primary progressive aphasia , alzheimer's disease , endocrinology , pathology , disease , dementia , frontotemporal dementia

Accurate diagnosis of sporadic early-onset Alzheimer's disease (EOAD) can be challenging, and cerebrospinal fluid (CSF) biomarkers may assist in this process. We compared CSF indices between three EOAD subtypes: amnestic, logopenic progressive aphasia (LPA), and posterior cortical atrophy (PCA).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research